The present disclosure relates in part to coating compositions comprising a bactericidal layer further comprising a bactericidal element and a columnar microstructure, which exerts bactericidal activity toward proximal and distal bacteria within an electrolyte solution (i.e. blood or other bodily fluid). The present disclosure further relates to coating compositions stably adhered to an electrode, which exerts bactericidal activity toward proximal and distal bacteria within an electrolyte solution upon application of an electric potential to the underlying electrode without a loss in efficiency of charge transfer.

A suture or a surgical or wound closure staple is disclosed that includes protocatechuic acid. The protocatechuic acid may be coated on, or impregnated in, the suture or wound closure staple. The suture or wound closure staple may include polypropylene, nylon, polyester, and/or braided polyester, catgut, 85/15 D,L lactide/glycolide, and/or 910 Vicryl. The protocatechuic acid may coat 25% or more of the surface of the suture or surgical staple. In embodiments, the protocatechuic acid may have a purity of 95% or greater. The protocatechuic acid may include crystalline protocatechuic acid.

Compositions are provided that have at least two of three active ingredients. The active ingredients maybe a salt having a cation N.sup.αC8-C16 alkanoyl-L di-basic amino acid —C1-C4 alkyl ester, a glycerol monoester of a fatty acid and a sugar ester of a fatty acid. The compositions are useful in methods of killing or inhibiting planktonic bacteria or fungi and bacteria or fungi embedded in a biofilm and prevention of biofilm formation on surfaces. The composition may further comprise a hydrogel and a benefit agent such as an antibiotic that can be solubilized by the hydrogel and supplied to the biofilm matrix by the active ingredients of the composition. Devices such as chronic wound coverings coated with the composition are also provided. Methods of preserving products with the composition are also provided.

The inventors of the technology disclosed herein have developed triblock copolymers of lactide-containing polyesters and poly(ethylene glycol), PEG, having thermoresponsive properties.

The present invention relates to a thread embedding therapy rope and a thread embedding therapy needle apparatus comprising same, and disclosed are a thread embedding therapy rope and a needle apparatus comprising same, the rope comprising a linear core, which comprises a biodegradable polymer, and a metal wire, which is arranged to spirally encompass the outer circumferential surface of the linear core, wherein the metal wire comprises a biodegradable metal formed with magnesium or zinc as a main component, so as to have no side effects on biological tissue when applied to the human body by means of thread embedding therapy, pulling force on the tissue can be strengthened, lifespan can be extended over that of a conventional embedded thread of a biodegradable polymer, the drug loading capability of the embedded thread itself can be increased so as to allow for usefulness as a drug carrier, and a drug can be delivered through a simple method.

Hollow fiber drug delivery devices are described. Device can contain structural or solid fibers. Fabric can be formed by fibers being interwoven or joined to each other. All or some of the fibers can be resorbable. Fibers can be subdivided, by deformations or closure points, into numerous compartments that separately deliver drug. Deformations can be located at points of fiber intersection or joining. Different drug or drug formulation can be provided in different places. Fibers can be given appropriate surface treatments or coatings to achieve desired properties such as wetting of pores and surfaces. Different release characteristics in different directions can be achieved. The hollow fibers can contain solid particles of drug, and can contain gel. Possible applications include hernia meshes, pouches, sutures, catheters, wound dressings, stents, nerve regrowth guides, refillable/drainable devices, and devices that deliver drug to lymphatic flow.

The filament and suture products disclosed are to be implanted in the body, having non re sorbable ingredients with absorbent qualities to disperse an antibiotic and strong enough to hold tissue securely but flexible enough to be printed or knotted. The products are biocompatible and consist of two dissimilar polymers having unmelted cellulose fiber. These dissimilar polymers and the unmelted fibers are densified by compression and the removal of moisture having fiber orientation and alignment, showing low levels of radiopacity. These products will have radiopacity in household units (HU) ranging from −200 to 200 HU and produce meshes, bone grafts, scaffolds or wound care products where bone bridging can be observed.

Resorbable implants comprising poly(butylene succinate) and copolymers thereof have been developed. The implants implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing, and the fibers may be oriented. Coverings and receptacles made from forms of poly(butylene succinate) and copolymers thereof have also been developed for use with cardiac rhythm management devices and other implantable devices. These coverings and receptacles may be used to hold, or partially/fully cover, devices such as pacemakers and neurostimulators. The coverings and receptacles are made from meshes, webs, lattices, non-wovens, films, fibers, and foams, and contain antibiotics such as rifampin and minocycline.

The present invention provides peptidic TGF-β antagonists capable of inhibiting TGF-β signaling and disrupting the biochemical events that promote fibrosis and the epithelial-mesenchymal transition. The peptidic TGF-β antagonist may contain from 11 to 28 amino acid residues (for instance, may consist of from 12 to 16 amino acid residues) and may have the following structure (II):
NH.sub.2′ETWIWLDTNMG-Xaa.sub.1-Y′COOH  (II)
wherein Xaa.sub.1 is any amino acid and Y is a peptide having from 0 to 9 amino acids. The peptidic TGF-β antagonists can advantageously be used for the prevention, treatment, and/or alleviation of the symptoms of a condition associated with an increase in TGF-β activity, including fibrosis (such as fibrosis of the skin, liver, lungs, and heart, among others) and cancer (including various carcinomas, such as squamous cell carcinoma, sarcomas, and metastatic cancers).

A disposable coating applicator container for applying a coating of a therapeutic agent upon an object to be coated. The disposable coating applicator container includes a sealable container, the sealable container having a container bottom, the container bottom having upwardly extending walls, each upwardly extending wall terminating in an upper edge, and a closure for sealing a device compartment formed in part by the upwardly extending walls, the closure adjacent to the upper edges of the upwardly extending walls; and a therapeutic agent positioned in fluid communication with the device compartment, wherein the disposable coating applicator container comprises a flexible material and is in the form of a bag-like structure.